PDF(Pubmed)
Abstract：
Although intravenous thrombolysis with alteplase remains the primary treatment for acute ischemic stroke, tenecteplase has shown potential advantages over alteplase. Animal studies have demonstrated the favorable pharmacokinetics and pharmacodynamics of tenecteplase. Moreover, it is easier to administer. Clinical trials have demonstrated that tenecteplase is not inferior to alteplase and may even be superior in cases of acute ischemic stroke with large vessel occlusion. Current evidence supports the time and cost benefits of tenecteplase, suggesting that it could potentially replace alteplase as the main option for thrombolytic therapy, especially in patients with large vessel occlusion.
摘要：
尽管阿替普酶静脉溶栓仍然是急性缺血性卒中的主要治疗方法，替奈普酶显示出优于阿替普酶的潜在优势。动物研究表明，替奈普酶具有良好的药代动力学和药效学。此外，管理起来更容易。临床试验表明，替奈普酶并不逊色于阿替普酶，甚至在急性缺血性卒中伴有大血管闭塞的情况下可能更好。目前的证据支持替奈普酶的时间和成本优势，这表明它有可能取代阿替普酶作为溶栓治疗的主要选择，尤其是大血管闭塞患者。
